References from scientific journals

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN. Baselga J, et al. N Engl J Med. 2012 Feb 9;366(6):520-9. doi: 10.1056/NEJMoa1109653. Epub 2011 Dec 7. N Engl J Med. 2012. PMID: 22149876 Free PMC article. Clinical Trial.

The most common grade 3 or 4 adverse events were stomatitis (8% in the everolimus-plus-exemestane group vs. 1% in the placebo-plus-exemestane group), anemia (6% vs. <1%), dyspnea (4% vs. 1%), hyperglycemia (4% vs. <1%), fatigue (4% vs. 1%), and pneumonitis (3% …
The most common grade 3 or 4 adverse events were stomatitis (8% in the everolimus-plus-exemestane group vs. 1% in the placebo-plus- …

Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial.

Jerusalem G, de Boer RH, Hurvitz S, Yardley DA, Kovalenko E, Ejlertsen B, Blau S, Özgüroglu M, Landherr L, Ewertz M, Taran T, Fan J, Noel-Baron F, Louveau AL, Burris H. Jerusalem G, et al. JAMA Oncol. 2018 Oct 1;4(10):1367-1374. doi: 10.1001/jamaoncol.2018.2262. JAMA Oncol. 2018. PMID: 29862411 Free PMC article. Clinical Trial.

IMPORTANCE: Everolimus plus exemestane and capecitabine are approved second-line therapies for advanced breast cancer. ...Estimated HR of PFS was 0.74 (90% CI, 0.57-0.97) for the primary objective of everolimus plus exemestane vs everolimus alone and 1.26 (90% CI, 0 …
IMPORTANCE: Everolimus plus exemestane and capecitabine are approved second-line therapies for advanced breast cancer. ...Estimated H …

Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial.

Johnston SR, Kilburn LS, Ellis P, Dodwell D, Cameron D, Hayward L, Im YH, Braybrooke JP, Brunt AM, Cheung KL, Jyothirmayi R, Robinson A, Wardley AM, Wheatley D, Howell A, Coombes G, Sergenson N, Sin HJ, Folkerd E, Dowsett M, Bliss JM; SoFEA investigators. Johnston SR, et al. Lancet Oncol. 2013 Sep;14(10):989-98. doi: 10.1016/S1470-2045(13)70322-X. Epub 2013 Jul 29. Lancet Oncol. 2013. PMID: 23902874 Free article. Clinical Trial.

Participants and investigators were aware of assignment to fulvestrant or exemestane, but not of assignment to anastrozole or placebo. The primary endpoint was progression-free survival (PFS). ...FINDINGS: Between March 26, 2004, and Aug 6, 2010, 723 patients underwent ran …
Participants and investigators were aware of assignment to fulvestrant or exemestane, but not of assignment to anastrozole or placebo …

Everolimus-based combination therapies for HR+, HER2- metastatic breast cancer.

O'Shaughnessy J, Thaddeus Beck J, Royce M. O'Shaughnessy J, et al. Cancer Treat Rev. 2018 Sep;69:204-214. doi: 10.1016/j.ctrv.2018.07.013. Epub 2018 Jul 23. Cancer Treat Rev. 2018. PMID: 30092555 Free article. Review.

Advances in treating this type of MBC have focused on improving the efficacy of endocrine therapy by adding agents that target specific molecular pathways of breast cancer cell growth and survival. The combination of the aromatase inhibitor exemestane and the mammalian tar …
Advances in treating this type of MBC have focused on improving the efficacy of endocrine therapy by adding agents that target specific mole …

Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis.

Yardley DA, Noguchi S, Pritchard KI, Burris HA 3rd, Baselga J, Gnant M, Hortobagyi GN, Campone M, Pistilli B, Piccart M, Melichar B, Petrakova K, Arena FP, Erdkamp F, Harb WA, Feng W, Cahana A, Taran T, Lebwohl D, Rugo HS. Yardley DA, et al. Adv Ther. 2013 Oct;30(10):870-84. doi: 10.1007/s12325-013-0060-1. Epub 2013 Oct 25. Adv Ther. 2013. PMID: 24158787 Free PMC article. Clinical Trial.

Initial Breast Cancer Trials of OraL EveROlimus-2 (BOLERO-2) trial data demonstrated that everolimus and exemestane significantly prolonged progression-free survival (PFS) versus placebo plus exemestane alone in this patient population. METHODS: BOLERO-2 is a phase …
Initial Breast Cancer Trials of OraL EveROlimus-2 (BOLERO-2) trial data demonstrated that everolimus and exemestane significantly pro …

Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial.

Goss PE, Ingle JN, Pritchard KI, Ellis MJ, Sledge GW, Budd GT, Rabaglio M, Ansari RH, Johnson DB, Tozer R, D'Souza DP, Chalchal H, Spadafora S, Stearns V, Perez EA, Liedke PE, Lang I, Elliott C, Gelmon KA, Chapman JA, Shepherd LE. Goss PE, et al. J Clin Oncol. 2013 Apr 10;31(11):1398-404. doi: 10.1200/JCO.2012.44.7805. Epub 2013 Jan 28. J Clin Oncol. 2013. PMID: 23358971 Free PMC article. Clinical Trial.

PATIENTS AND METHODS: We designed an open-label, randomized, phase III trial of 5 years of exemestane versus anastrozole with a two-sided test of superiority to detect a 2.4% improvement with exemestane in 5-year event-free survival (EFS). ...RESULTS: In the study, …
PATIENTS AND METHODS: We designed an open-label, randomized, phase III trial of 5 years of exemestane versus anastrozole with a two-s …

Exemestane.

Scott LJ, Wiseman LR. Scott LJ, et al. Drugs. 1999 Oct;58(4):675-80; discussion 681-2. doi: 10.2165/00003495-199958040-00007. Drugs. 1999. PMID: 10551437 Review.

Exemestane is a steroidal agent which causes inactivation of the aromatase enzyme by binding irreversibly to the substrate binding site. ...Results from a phase III trial indicate that exemestane achieves a similar objective response rate to megestrol as a second-li …
Exemestane is a steroidal agent which causes inactivation of the aromatase enzyme by binding irreversibly to the substrate binding si …

Bioequivalence of exemestane in post-menopausal females.

Groenewoud G, Nell A, Potgieter L, Seiler D, Wettmarshausen C. Groenewoud G, et al. Arzneimittelforschung. 2010;60(2):96-100. doi: 10.1055/s-0031-1296255. Arzneimittelforschung. 2010. PMID: 20329658 Clinical Trial.

In each treatment phase subjects received a single dose (one tablet) of 25 mg exemestane (CAS 107868-30-4). Consecutive dosing was separated by a drug-free washout period of 21 d. Following each dosing, serial venous blood samples were collected over a period of 144 h for …
In each treatment phase subjects received a single dose (one tablet) of 25 mg exemestane (CAS 107868-30-4). Consecutive dosing was se …

Breast Cancer Risk-Reducing Medications.

Graham D, DiNome ML, Ganz PA. Graham D, et al. JAMA. 2020 Jul 21;324(3):310. doi: 10.1001/jama.2020.11784. JAMA. 2020. PMID: 32692388 No abstract available.


Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor-positive breast cancer: A multicenter, open-label, phase II study.

Sato N, Masuda N, Morimoto T, Ueno T, Kanbayashi C, Kaneko K, Yasojima H, Saji S, Sasano H, Morita S, Ohno S, Toi M. Sato N, et al. Cancer Med. 2019 Sep;8(12):5468-5481. doi: 10.1002/cam4.2423. Epub 2019 Jul 30. Cancer Med. 2019. PMID: 31361400 Free PMC article. Clinical Trial.

Our aim was to investigate the efficacy and safety of initial neoadjuvant endocrine therapy with exemestane alone followed by tailored treatment, either continued exemestane monotherapy or exemestane plus docetaxel-cyclophosphamide (TC) combination therapy, i …
Our aim was to investigate the efficacy and safety of initial neoadjuvant endocrine therapy with exemestane alone followed by tailore …